1. Effect-based monitoring tools Ispra 18 June 2012; CMEP meeting Ann-Sofie Wernersson, Mario Carere, Chiara Maggi ann-sofie.wernersson@havochvatten.seann-sofie.wernersson@havochvatten.se; Mario.carere@iss.it; chiara.maggi@isprambiente.itMario.carere@iss.it chiara.maggi@isprambiente.it

2. Drafting group Activity leaders Ann Sofie Wernersson (Sweden) Mario Carere (Italy) Chiara Maggi (Italy) Group Petr Tusil, Premysl Soldan (Czech Republic) Antonella Ausili, Loredana Manfra, Francesco Regoli, Laura Marziali (Italy) Bernd Gawlik (JRC) Teresa Lettieri (JRC) Robert Kase, Cornelia Kienle, Petra Kunz, Etienne Vermeissen, Inge Werner (Switzerland) Alice James (Ineris-France) Hannie Maas, Esther Van Der Grinten (Netherland) Werner Brack (Norman-Germany) Wilfried Sanchez (Norman-France) Valeria Dulio (Norman) Henner Hollert (Germany) Klaas den Haan (Concawe) Marlies Messiaen (Eurometaux) Karl Lilja (Sweden)

3. Drafting group meetings in Switzerland (Dübendorf; Oekotoxzentrum) Nov 2011 May 2012 And commenting rounds…now 4th version

4. Structure of version 4 1.Introduction 2.Use of effect-based tools in the WFD monitoring programmes 3.Standardisation and validation of effect-based tools 4.Effect-based tools currently available for WFD use 5.Integrated monitoring and evaluation of results 6.EDA and TIE 7.Novel tools 8.Case studies 9.Biomarker and in vitro assay fact sheets 10.Assessment criteria for individual tools

5. Chapter 1: Introduction Aim Current use in Europe – Regional Sea Conventions, MSFD – National level use Illustrates different purposes identified so far, but also availability of national experience to consult (handbooks, criteria, performers), and baseline data available Please check current use on national level! Assessment criteria? Handbooks/guidance available?

6. Examples Regular (primarily marine?) trend monitoring; e.g. CEMP and preCEMP within OSPAR Investigations at contaminated sites (sediment) Evaluation of dredged sediment Whole Effluent Assessment Close to point sources (operator recipient control; PPP) Screening campaigns (certain types of sources; e.g. landfill leachates)

7. Chapter 2: Use of effect based tools in the WFD monitoring programmes Description of Chemical/ecological status; EQS, biological quality elements; surveillance-operational- investigative WFD monitoring Purpose: to understand and relate to overall WFD context Chapter 2.4.: Objectives and approaches within WFD context Purpose: to identify appropriate use and approaches within different contexts; within WFD and on a general level. (Case studies, fact sheets and ch. 4 for more details)

8. The (currently) seven objectives 1.Prioritisation of areas – to support analysis of pressure and impacts 2.Early warning – on surveillance level 3.Alarm system to aid discover probable MAC exceedence 4.To support compliance check (e.g. screening level – if more sensitive, investigate bioavailability, expert judgement regarding ecological status) 5.To reduce monitoring frequency – to support design 6.To select RBSPs – to support design 7.To identify important sources – to support River Basin Management Plan Please check suggestions; acceptable? Any objectives missing? Possible to understand?

9. Chapter 3: Standardisation and validation Bioassays – Procedures – Aspects considered – Special considerations in a monitoring context (esp surface water) Biomarkers Under construction….

10. Chapter 4: Tools currently available (in regular use) General technical descriptions of categories: – In vitro bioassays – In vivo bioassays – Biomarkers More detailed than ch 2, but less detail than in fact sheets etc Under construction….

11. Chapter 5: Integrated monitoring and evaluation of results Integrated monitoring approach (Chem, Tox, Biol) WOE (Weight of Evidence) – how to evaluate different types of data Under construction…. Aid in evaluation of status, support management

12. Chapter 6: EDA and TIE Components Bioavailability WFD context – to link effects/ecological status to chemical causes Please comment on text; suggested approaches, WFD applicability, description

13. Chapter 7: Novel tools OMICS; e.g. Microarray, Real Time PCR, Community level bioindicators; e.g. SPEAR, PICT Under construction….

14. Chapter 8: Case studies To illustrate and cover primarily the objectives identified in chapter 2.3. using the tools described in chapter 4 and fact sheets (ch. 9). Other illustrative use may also be included (e.g. novel tools, integrated evaluation etc) Approx 1-3 pages Under construction…. Particular cases requested? Possible to donate, based on national experience (see ch 1)

15. Chapter 9: Fact sheets Purpose: to aid the user in proper design, depending on purpose Practical aspects, such as: – Test reference (standards etc) – Evaluation of results – What does it respond to (e.g. metals, Ah receptor active compounds, but also other influencing factors) (biomarkers) – What species (e.g. marine/limnic fish) can be analysed? What tissue? Season to be avoided? (biomarkers) – What matrices can be analysed (sediment, tissue, water)? Commercial availability? (in vitro bioassays) – Costs (sampling/analysis) – Etc….(see page 111-130) Under construction…. Please check HEADERS; any missing that would be valuable to facilitate design? Please suggest additional tools that you wish should be described!

16. Chapter 10: Assessment criteria Currently available, on national and international levels (monitoring purposes) – For biomarkers – For bioassays

17. By Sept 7th we want Your comments/info on (ch 1 and 2): Current use of effect based tools in Your country; for what type of purposes? Available handbooks/guidance? Available assessment criteria? – See e.g. also ch 10 For monitoring purposes: what individual tools are regularly used ? – See e.g. also table in chapter 4.; what bioassays are used within marine MONITORING Are all WFD uses/objectives included? Acceptable? Are the descriptions of approaches acceptable from a regulatory perspective? Further guidance wanted on suitable approaches at this stage? Or too much detail? Possible to understand (terms used)? Right order (common thread)?

18. And… Fact sheets: – HEADERS – additional requests? – Biomarkers/ in vitro assays included – additional tools that should be described too? EDA/TIE: – Description, approach etc Case studies – Particular case studies requested? – Donations? (based on current use on national levels, ch 1, – if WFD context can be perceived)